Skip to main content

Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

Treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors may improve patients’ overall psychiatric condition in addition to reducing TD symptoms, a study of real-world data found.
In this video, psychiatrist Richard Jackson, MD, speaks about assessing and monitoring tardive dyskinesia during telepsychiatry visits.
Patients taking valbenazine saw persistent improvements in tardive dyskinesia (TD) symptoms for more than a year, researchers found in a long-term open-label study.
In this video, Leslie Citrome, MD, MPH, details 5 steps to success for clinicians treating patients who have tardive dyskinesia or are at risk of the disorder.
In this video, Psych Congress Steering Committee member Rakesh Jain, MD, MPH, offers guidance on the proper treatment of tardive dyskinesia (TD) during the COVID-19 pandemic.
Back to Top